Core Viewpoint - The approval of Fu'en Co., Ltd.'s IPO registration by the China Securities Regulatory Commission (CSRC) highlights the acceleration of the IPO review process in the Chinese market, with significant reductions in the time taken for companies to move from application to registration [2][3][4]. Group 1: IPO Approval Process - Fu'en Co., Ltd.'s IPO application was accepted on June 24, 2025, and took approximately 206 days to complete the registration [2][3]. - In less than twenty days, the CSRC issued registration approvals for eight IPO companies, with most companies experiencing a queue time of less than eight months [3][4]. - The average review time for 82 companies that received registration from June 18, 2025, to January 16, 2026, was 472 days, with the average for the fourth quarter of 2025 dropping to 393 days [4][5]. Group 2: Increase in IPO Applications - The number of IPO applications received by the three major exchanges in 2025 was 251, which is 3.26 times that of 2024 [4][14]. - The CSRC approved a total of 84 IPO applications from June 18, 2025, to January 16, 2026, including 17 from the Sci-Tech Innovation Board and 31 from the Beijing Stock Exchange [4][14]. Group 3: Focus on Technology Companies - The acceleration in the review process is particularly evident for technology companies, with a notable emphasis on hard-tech enterprises that align with national strategies [8][18]. - For instance, the fastest IPO approval was for Nanfang Network Digital, which took only 112 days from acceptance to registration [17][18]. Group 4: Regulatory Environment - Despite the faster approval process, the regulatory environment remains stringent, with a slight decrease in the approval rate to 93% in the fourth quarter of 2025 [19][20]. - The CSRC has maintained a focus on quality, ensuring that while the pace of approvals increases, the standards for entry into the market remain high [20].

Group 1 - The IPO review process has accelerated, with six companies scheduled for meetings this week, all of which were accepted after May this year, indicating a shift from "queue theory" to focusing on "quality" [1] - High-quality companies are now able to bypass lengthy waiting periods, allowing them to access capital markets more quickly for financing, which is crucial for sectors like hard technology and innovative pharmaceuticals that require significant R&D investment [1] - The ability to quickly secure funding will empower these companies to enhance R&D, improve technology levels, and expand production capacity, which is significant for their growth into unicorns [1] Group 2 - The shift in focus to "quality" creates a pressure mechanism for companies to improve their core competitiveness and solidify their fundamentals, emphasizing the need for advancements in technology, product quality, and management [2] - This pressure mechanism is expected to elevate the overall quality of companies preparing for IPOs, promoting a transition from short-term profit pursuits to long-term development, fostering a healthy competitive market environment [2] - The listing of high-quality IPO companies will enhance the overall quality of the A-share market, attracting more long-term capital and improving market stability and appeal [2] Group 3 - To ensure that high-quality IPO companies maintain their position, it is essential to improve relevant systems and regulatory mechanisms, including stricter information disclosure audits to prevent fraudulent listings [3] - A robust market exit mechanism should be established to eliminate underperforming companies, maintaining market vitality and health [3] - Intermediary institutions must fulfill their roles diligently to promote the standardized operation of listed companies, which will help purify the A-share market and protect the rights of small investors [3]